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Abstract
Background: mTORC1 (mammalian target of rapamycin complex 1) activation has been demonstrated in response to
endotoxin challenge, but the mechanism and significance are unclear. We investigated the effect of mTORC1 suppression in
an animal model of endotoxemia and in a cellular model of endotoxin signaling.
Methodology/Principal Findings: Mice were treated with the mTORC1 inhibitor rapamycin or vehicle prior to lethal
endotoxin challenge. Mortality and cytokine levels were assessed. Cultured macrophage-like cells were challenged with
endotoxin with or without inhibitors of various pathways known to be upstream of mTORC1. Activated pathways, including
downstream S6K pathway, were assessed by immunoblots. We found that mTORC1-S6K suppression by rapamycin delayed
mortality of mice challenged with lethal endotoxin, and was associated with dampened circulating levels of VEGF, IL-1b, IFN-
c and IL-5. Furthermore, in vitro cellular studies demonstrated that LPS (lipopolysaccharide) activation of mTORC1-S6K still
occurs in the presence of PI3K-Akt inhibition alone, but can be suppressed by concurrent inhibition of PI3K-Akt and MEK-
ERK pathways.
Conclusions/Significance: We conclude that cellular activation of mTORC1-S6K contributes to cytokine up-regulation and
mortality in response to endotoxin, and may occur via multiple pathways.
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Introduction
Mammalian target of rapamycin (mTOR) is a serine/threonine
kinase that regulates protein production essential for cellular
proliferation. mTOR functions in two distinct complexes: mTOR
complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
mTORC1 phosphorylates p70S6K (S6K) and 4EBP-1, leading to
translational activation, ribosome biogenesis, and metabolic
responses partly due to ribosomal protein S6 and eIF4E.
mTORC1 is regulated by several interacting proteins, most
significantly by levels of rheb-GTP, which are in turn regulated by
the GTPase activating (GAP) activity of the TSC1/TSC2
complex. TSC1/TSC2 receives input signals from PI3K-Akt,
WNT-GSK3, AMPK, and MAPK pathways and others, through
phosphorylation events that reflect cellular energy stress, nutrient
availability, and growth factor activation[1,2]. Because of its
essential role in cellular proliferation and frequent deregulation in
cancer, mTOR has been intensively studied, leading to the use of
rapamycin, a highly specific and potent mTORC1 inhibitor [3], in
various forms of cancer[1,4]. The role of mTOR in innate
immunity has also begun to receive attention. It’s been recognized
that lipopolysaccharide (LPS) activates mTORC1 in various types
of cells, such as neutrophils, monocytes, macrophages and
dendritic cells[5,6,7,8], presumably via PI3K-Akt path-
way[2,9,10]. In addition, a porcine model of endotoxemia
demonstrated mTORC1 activation in the liver but not mus-
cle[11]. However the precise mechanism and significance of
mTORC1 activation are not completely understood. For example,
mTORC1 inhibition appears to be beneficial in one animal model
of systemic inflammation[8], while in another animal model, there
appears to be a detrimental effect from rapamycin treatment[7].
We report here that treatment of mice with endotoxin leads to
mTORC1-dependent up-regulation of specific cytokines contrib-
uting to early endotoxemic lethality, and that LPS activates
mTORC1 independent of PI3K-Akt pathway. Our data suggest
mTORC1 may be a modifiable target in systemic inflammatory
response.
Materials and Methods
Murine endotoxemia and rapamycin preparation
Wild type C57BL/6 male (Charles River Laboratories,
Wilmington, MA), TNF-a receptor-null mutant (p55 and p75
double TNFR knockout) male mice[12] (the Jackson Laboratory,
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and the Harvard Medical Area Standing Committee on Animals
approved all procedures described (ARCH Protocol #07-09-
1485R), according to standards as set forth in The Guide for the
Care and Use of Laboratory Animals.
Rapamycin and vehicle were prepared as described previously
[13,14]. Briefly, rapamycin (LC Laboratories, Woburn, MA)
dissolved at 20 mg/ml in ethanol was diluted in 0.25% Tween 80,
0.25% polyethylene glycol 400 (0.5–1.5 mg/ml). We had
previously shown that rapamycin given at 6 mg/kg i.p. in mice
is sufficient to maintain plasma rapamycin levels within the
therapeutic ranges for at least 48 hr [13]. Eighteen 8–12 week old
male C57BL/6 mice each weighing 18–20 g were injected i.p.
with 25 mg/kg LPS (Escherichia coli O55:B5, Sigma, St. Louis, MO)
and immediately resuscitated with 1 ml s.c. injections of PBS.
Treatment with vehicle (9 mice) or 6 mg/kg rapamycin (9 mice)
i.p. was given 30 min prior to LPS challenge. The mice were
anesthetized for plasma and organ collections and then euthanized
at 2, 6, and 24 hr (3 mice per group sacrifice at each time point)
post LPS challenge. In addition, mice without LPS challenge
served as controls. In a separate mortality experiment, mice
received the same LPS challenge and were allocated to receive
vehicle (10 mice) or rapamycin (6 mg/kg) (9 mice) treatment prior
to LPS as described. The animals were monitored frequently, and
survival was recorded for 5 days. Surviving mice were euthanized.
Cytokine measurements
Plasma GM-CSF, IFN-c, IL-1b, IL-2, IL-5, IL-6, IL-10, IL-12
and TNF-a cytokines were measured using a multiplex immuno-
assay assay (Millipore, Billerica, MA). The lower range of the assay
is ,3.2 pg/ml for each cytokine, and levels ,3.2 pg/ml were
assigned a value of zero. VEGF (vascular endothelial growth
factor) was assayed using a commercial ELISA kit (R&D Systems,
Minneapolis, MN) as directed.
Organ protein extraction
Organs extracted from mice were mechanically homogenized in
RIPA buffer (Boston Bioproducts, Boston, MA) supplemented with
protease inhibitor cocktail (Roche, Indianapolis, IN) and a
phosphatase inhibitor (Thermo Scientific, Waltham, MA), and
incubated on ice for 30 min before centrifugation to remove
insoluble tissue debris. Supernatant extracts were assayed for
protein concentration by Bradford assay (BioRad Laboratories
Inc. Hercules, CA) and normalized before immunoblotting.
Cell Culture
Wortmannin, LY294002, and U0126 were purchased from Cell
Signaling, Danvers, MA. Unless otherwise specified, cell culture
media and supplements were from Invitrogen, Carlsbad, CA.
Murine macrophage-like cells, RAW 264.7(ATCC, Manassas,
VA, USA) were maintained in DMEM (Dulbecco’s Modified
Eagle’s Medium) supplemented with 10% FBS and 1% penicillin-
streptomycin-amphotericin B (PSA), in an incubator at 37uCi n
5% CO2, until confluent. Primary murine peritoneal macrophages
were harvested by peritoneal lavage of wild type C57BL/6 mice
72 hr after injection of 1.5 ml 2% thioglycolate media (Sigma, St
Louis, MO). Primary cells from peritoneal lavage were placed on
culture dishes in DMEM with10%FBS and 1%PSA, at 37uC, 5%
CO2, and washed daily with fresh media to remove non-adherent
cells for at least 5 days before experiments. Tsc2-null murine
embryonic fibroblasts (MEFs) have been previously described from
our lab[15]. The cells were seeded on 6-well plates at
500,000 cells/ml 24 hr prior to experiments. Inhibitors were
added 30 min prior to LPS (100 ng/ml), and cells were harvested
2 hr post LPS.
RNA Interference Studies
Small-interfering RNA (siRNA) constructs were purchased from
Ambion (Austin, TX), and used as instructed by the manufacturer.
Briefly, 30 nM (IKKb) or 80 nM (raptor) of Silencer siRNA
constructs against IKKb (s68175), raptor (s92712) or nonsense
negative control of corresponding concentration were incubated in
Opti-MEM (Invitrogen, Carlsbad, CA) with NeoFX (Ambion) or
RNAiMAX (Invitrogen) transfection agent. The mixture was then
plated into 6 or 12-well plates and overlaid with 1.5610
5 cells/ml
in Opti-MEM for 24 hr. Media was replaced with fresh DMEM
with 10%FBS, 1%PSA and incubated for another 24 hr before
LPS challenge.
Figure 1. mTORC1-S6K up-regulation in the livers, lungs, and
kidneys of mice treated with endotoxin. Representative immuno-
blots of normalized organ protein extracts probed for pS6 (S240/244), a
downstream target of mTORC1-S6K are shown here. Mice were
subjected to 25 mg/kg of LPS i.p. and sacrificed at 2,6, and 24 hr later.
Untreated mice served as time 0 hr controls. mTORC1-S6K activation
could be seen as early as 2 hr after LPS challenge in the livers and lungs
of endotoxemic mice. mTORC1-S6K was also activated in the kidneys at
24 hr post challenge. Increased pAkt (S473) was seen only in the lung
extracts post LPS challenged, occurring at 6 hr post LPS, after mTORC1-
S6K activation, and was not seen in either liver or kidney.
doi:10.1371/journal.pone.0014399.g001
LPS Activation of mTORC1
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Protein samples were analyzed by SDS-PAGE using 4–12%
NuPAGE Gel (Invitrogen), and transferred to a nitrocellulose
membrane. Immunoblotting was performed by standard methods
using HRP-conjugated secondary antibodies, and chemilumines-
cence using Supersignal West Pico Chemilumincesent substrate
(Thermo Fisher Scientific, Pittsburgh, PA) and exposure to film.
All antibodies, except anti-tubulin (Abcam, Cambridge, MA) were
purchased from Cell Signaling.
Statistics
Statistical analyses were performed using Prism 4 (Graphpad
Software, La Jolla, CA). Survival curves were plotted using the
method of Kaplan and Meier and analyzed using the logrank test.
Temporal cytokine levels between 2 groups were compared by
Repeated Measures ANOVA. A p-value,0.05 was considered
significant.
Results
mTORC1-S6K was highly activated in lungs, kidneys, and
livers of mice treated with LPS, as assessed by an increase in
phosphorylated S6(S240/244) (pS6,S240/244). This occurred
within 2 hr of LPS challenge in the liver and lung, and persisted
for at least 24 hr (Figure 1). PI3K-Akt activation (pAkt,S473),
however, could only be demonstrated in the lungs after
mTORC1-S6K activation, 6 hr post LPS challenge. These data
suggest that mTORC1-S6K up-regulation in organs of en-
dotoxemic mice may occur without PI3K-Akt activation.
Since mTORC1-S6K was highly activated by LPS treatment,
we explored the effects of rapamycin treatment on this activation
and other events occurring during the subsequent endotoxic
shock in these mice. Rapamycin (6 mg/kg) administration
30 min before LPS effectively suppressed mTOC1-S6K activa-
tion in all tissues (Figure 2). In addition, cytokine profiling
demonstrated that rapamycin pre-treatment led to significant
down-regulation in the expression of several cytokines: IL-1b,I L -
5, IFN-c, and VEGF as shown in Figure 3. The suppressive effect
by rapamycin treatment is especially apparent 24 hr post LPS
treatment. In contrast, levels of IL-2, IL-6, IL10, IL-12, and GM-
CSF showed no significant change while TNF-a showed a trend
toward lower levels with rapamycin treatment (P=0.058). These
effects correlated with a transient improvement in mortality in
these mice following lethal endotoxin injection (Figure 4).
However, notably, this single pre-LPS dose of rapamycin did
not prevent late mortality. Our data are in contrast with a
previous report of rapamycin enhancing IL-1b production in
endotoxemic animals[7] and more consistent with a recent report
of lower pro-inflammatory TNF-a and IL-6 in response to LPS
by rapamycin treatment[5]. We also did not observe a significant
alteration of IL-10/IL-12 induction following LPS with rapamy-
cin treatment, in contrast to previous reports on cultured cells
treated with LPS[6,8].
TNF-a is thought to activate mTORC1 through IKKb
phosphorylation and inactivation of TSC1[16]. This is a
potential mechanism by which LPS treatment leads to
mTORC1-S6K activation in LPS-challenged animals, indepen-
dent of PI3K-Akt pathway. However, mTORC1-S6K activation
occurred equally well in mice deficient for TNF-a receptor
knockout, suggesting TNF-a signaling does not play a significant
role in mTORC1-S6K activation in endotoxemia (Figure 5). It
is important to note that without careful comparisons of the
degrees of mTORC1-S6K activation between wild type and
TNFR knockout mice, we could not rule out the possibility
of TNF-a playing a minor role in LPS induction of mTORC1-
S6K.
We also examined the effects of LPS treatment on macrophages
using RAW 264.7 murine macrophage-like cells. Knockdown of
raptor, an essential component of mTORC1, by siRNA blunted
LPS-induced increase in S6 phosphorylation at S240/244
(Figure 6) confirming that mTORC1 is activated by LPS leading
to S6K phosphorylation of S6.
Rapamycin sensitive LPS activation of mTORC1-S6K in RAW
cells occurred within 30 min of LPS challenge (Figure 7A), while
TNF-a levels were not detectably increased in the conditioned
media at that time point (Figure 7B). Therefore, it appears that
TNF-a appears is not required for mTORC1 activation response
in LPS-treated RAW cells.
Figure 2. Rapamycin treatment effectively suppressed mTORC1-S6K signaling. Following LPS challenge in vivo, mice were treated with
vehicle or 6 mg/kg rapamycin 30 min prior to 25 mg/kg LPS challenge. Organs were harvested from mice at 2, 6, 24 hr post challenge. Immunoblots
of organs extracted from 3 mice from each treatment group probed for pS6 (S240/244), a downstream target of mTORC1-S6K are shown here.
Unchallenged mice with or without rapamycin served as controls (time 0 hr). Rapamycin treatment successfully suppressed mTORC1-S6K up-
regulation in endotoxemic mice as reflected by the near-absent pS6 signals.
doi:10.1371/journal.pone.0014399.g002
LPS Activation of mTORC1
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e14399Figure 3. Rapamycin suppression of mTORC1-S6K was associated with lower cytokine levels. Following LPS treatment in vivo, circulating
cytokine levels of LPS-challenged mice pre-treated with vehicle (solid bar) or rapamycin (open bar) at 0 (no LPS), 2, 6, and 24 hr post LPS are shown
here. Data are expressed as mean of three mice in each group at each time point, with error bars representing standard deviations. Statistical analysis
was performed using Repeated Measures ANOVA, and p values,0.05 are considered as significant (*). mTORC1-S6K suppression by rapamycin led to
decreased circulation levels of IL1-b, VEGF, IFN-c and IL-5. There was a trend toward lower TNF-a levels with a p value of 0.058.
doi:10.1371/journal.pone.0014399.g003
LPS Activation of mTORC1
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‘‘specific PI3K inhibitors’’ such as wortmannin and LY294002
also can inhibit mTOR function when given at high
doses[17,18]. After preliminary studies examining dose-response
characteristics, we found that wortmannin (100 nM) and
LY294002 (12.5 mM) effectively suppressed PI3K-Akt signaling
in response to LPS, as assessed by phosphorylation of Akt at the
S473 site, but failed to inhibit mTORC1-S6K activation
(Figure 8). Thus, LPS activation of mTORC1 appears to be
independent of PI3K pathway, correlating with data from
endotoxemic mice.
Since IKKb can suppress TSC1 leading to mTORC1
activation [16], and LPS can activate IKKb directly [19], we
asked whether LPS activates mTORC1 via IKKb. Using siRNA,
Figure 9 shows that IKKb knockdown had no effect on LPS-
induced mTORC1-S6K activation in RAW cells, suggesting
IKKb is also not an essential component of LPS-induced
mTORC1-S6K activation.
Because ERK (extracellular signal-regulated kinase) can
phosphorylate and negatively regulate the GAP activity of
TSC2 and activate mTORC1[20], we examined whether
activation of ERK downstream of LPS is responsible for
mTORC1-S6K activation. MEK inhibitor U0216 given at a
dose that has no direct effect on mTORC1-S6K suppressed ERK
phosphorylation but did not completely suppress mTORC1-S6K
activation in LPS simulated RAW cells (Figure 10A). In addition,
wortmannin completely suppressed p-Akt(S473), but did not
completely abolished LPS-induced pS6 up-regulation. However,
the combination of wortmannin and U0216 completely sup-
pressed mTORC1-S6K activation by LPS, suggesting LPS may
activate mTORC1-S6K via MEK-ERK or PI3K-AKT pathway,
and neither pathway is required (Figure 10A). Similar experi-
ments on primary murine peritoneal macrophages yielded same
results (Figure 10B). We confirmed the lack of direct effect of
these inhibitors on mTORC1 in Tsc2-null murine embryonic
fibroblasts (MEFs). Figure 10C showed that mTORC1, which is
constitutively active in Tsc2-null cells, was not suppressed by
U0216 or wortmannin, either individually or in combination at
the doses used in this study.
Discussion
We have documented that mTORC1-S6K is activated in
several organs of mice challenged with LPS, that mTORC1-S6K
inhibition by rapamycin treatment leads to decrease in levels of
several inflammatory cytokines, such as IL-1band VEGF, and
transient improved survival, and that mTORC1-S6K activation
by LPS may occur with PI3K-Akt suppression. Because we have
focused on the initial activation of mTORC1 by LPS, only one
dose of rapamycin treatment was used in the animal mortality
experiment. It is certainly possible that repeated doses of
rapamycin may improve survival in this model. However we have
previously shown in another mouse model that this single dose of
rapamycin leads to persistent levels of rapamycin in serum and
liver lysates, well above the conventional therapeutic range, for at
least 48 hours [13], suggesting that there would be no major
Figure 4. Rapamycin suppression of mTORC1-S6K enhanced
early survival of endotoxemic mice. Kaplan-Meier curves of LPS-
challenged mice treated with vehicle control (N=10) or rapamycin
(N=9) are shown here. Rapamycin-treated mice had significantly better
survival compared to vehicle-treated (P=0.033, logrank test). However,
all mice had died by 72 hr after LPS challenge.
doi:10.1371/journal.pone.0014399.g004
Figure 5. mTORC1-S6K activation in endotoxemic TNFR-null
mice. Transgenic mice deficient in TNF-a receptors (TNFR) were given
LPS and sacrificed at 2, 6, and 24 hr later for organ extraction.
Representative immunoblots probed for pS6 (S240/244), a downstream
target of mTORC1-S6K are shown here. mTORC1-S6K activation could
be observed in the livers, lungs and kidneys of these mice similar to
wildtype mice.
doi:10.1371/journal.pone.0014399.g005
LPS Activation of mTORC1
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possibility will require additional study.
Our data are in distinct contrast to the study by Schmitz et al,
who reported that rapamycin treatment enhanced IL-1b levels
and worsened survival in mice challenged with lethal dose of
LPS[7]. However, several important differences between the two
studies may explain the contradictory findings. Schmitz et al
treated mice with a lower dose of rapamycin (1.5 mg/kg)
compared to the 6 mg/kg dose used in our study. Unfortunately,
Schmitz et al did not offer evidence of successful mTORC1
suppression in their study; therefore, it is possible that they did not
effectively suppress mTORC1. In addition, Schmitz et al treated
mice with daily rapamycin for 3 days prior to LPS challenge. It has
been recognized that extended rapamycin treatment can lead to
Figure 6. LPS activation of S6K was raptor dependent. RAW 264.7
cells were subjected to siRNA knockdown of raptor (RP), an essential
component of mTORC1 or nonsense control (NS). Cells were then
challenged with or without 100 ng/ml of LPS for 1 hr. Representative
immunoblotsshownheredemonstratedthebluntedLPSactivationofS6K,
as reflected by pS6 (S240/244) in cells subjected to raptor knockdown,
supporting that mTORC1 activation by LPS led to S6K activation.
doi:10.1371/journal.pone.0014399.g006
Figure 7. TNF-a secretion of LPS-treated macrophages oc-
curred after mTORC1-S6K activation. Conditioned media and cell
lysates of RAW cells treated with 100 ng/ml of LPS were collected at
various time points. The immunoblots probing for pS6(S240/244) (A.),
and the averages of TNF-a levels in the conditioned media from triplicate
experiments with error bars representing standard deviations (B.) are
shown here. mTORC1-S6K activation occurred as soon as 30 min after
LPS when TNF-a levels were not detectably increased at that time point.
doi:10.1371/journal.pone.0014399.g007
Figure 8. IKKb was not required for LPS-induced mTORC1-S6K
activation. IKKb was suppressed in RAW cells by siRNA (IK) 48 hr prior
to LPS stimulation. Nonsense siRNA constructs (NS) served as controls.
Representative immunoblots show that IKKb suppression had no effect
on mTORC1-S6K activation in LPS-treated RAW cells as reflected by pS6
levels.
doi:10.1371/journal.pone.0014399.g008
Figure 9. PI3K-Akt inhibition did not effect LPS-induced
mTORC1-S6K activation. RAW cells pre-treated with 100 nM
wortmannin, 12.5 mM LY294002, or vehicle control prior to 100 ng/ml
LPS challenge were collected 2 hr post LPS. Representative immuno-
blots demonstrating successful suppression of p-Akt with wortmannin
or LY294002 did not affect mTORC1-S6K activation as assessed by pS6
levels. Activation of ERK was also not affected by these compounds.
doi:10.1371/journal.pone.0014399.g009
LPS Activation of mTORC1
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treatment with rapamycin in Schmitz et al’s study might have
enhanced PI3K-Akt response to endotoxin leading to further
exaggerated inflammatory response. Finally, Schmitz et al tested
female mice while we studied male mice; gender differences in
LPS and rapamycin response may also explain different
observations.
Our findings are more consistent with the study by Lorne et al
who found rapamycin treatment suppressed pro-inflammatory
cytokines elicited by LPS[5]. In addition, we found VEGF
secretion is an mTORC1-S6K dependent process, similar to
other reports in cancer-related studies[22,23]. VEGF has been
implicated to play a significant role in acute respiratory distress
syndrome (ARDS) [24] and sepsis[25], and our data provide
additional target to intervene in VEGF-dependent pathology.
Therefore, mTORC1-S6K inhibition by rapamycin likely lessened
endotoxemia death by suppressing pathologic levels of cytokines,
such as IL-1b and VEGF.
Interestingly, rapamycin suppression of mTORC1-S6K also
reduced circulating levels of IL-5 and IFN-c. While mTOR has
been implicated in the IFN-induced signaling[26,27], our data
suggest mTORC1-S6K activation plays a critical role in IFN-c up-
regulation induced by LPS. These data suggest the possibility that
mTOR may have a previously unrecognized role in IFN-c and IL-
5 production.
We also report that LPS-induced mTORC1-S6K activation
does not necessarily depend on PI3K-Akt pathway as previously
believed[2,9,10]; rather, MEK-ERK may play a significant role
serving as an alternative pathway for mTORC1-S6K activation
by LPS. In tumor-like cells, ERK phosphorylates TSC2 leading
to the dissociation of TSC1/TSC2 complex with subsequent up-
regulation of mTORC1[20]. It is possible that the same
pathway is involved in LPS activated inflammatory cells, such
as macrophages. While the precise mechanism of how LPS-
TLR4 activates MEK-ERK pathway remains incompletely
understood, ERK activation appears to play a major role in
cellular cytokine secretion in response to LPS[19]. Our data
may point to mTORC1-S6K activation as a possible mecha-
nism of ERK-dependent cytokine production in response to
LPS.
In conclusion, we document the beneficial effect of mTORC1-
S6K suppression in an animal model of endotoxemia, associated
with down-regulation of several cytokines, including IL-1b and
VEGF, thought to be important in acute inflammatory response.
Furthermore, LPS can activate mTORC1-S6K with suppressed
PI3K-Akt, via alternative MEK-ERK pathway. Our data provide
new insight into LPS signaling and may support mTORC1 as a
possible target for therapeutic intervention in inflammatory
conditions.
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